Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT02101385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will test the theory that therapy designed for each individual's tumor will improve outcomes over standard of care in a population that needs a better standard.
Study identification
- NCT ID
- NCT02101385
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 193 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2, 2014
- Primary completion
- Feb 20, 2021
- Completion
- Sep 8, 2022
- Last update posted
- Sep 27, 2023
2014 – 2022
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Hematology Oncology Clinic at Medical West | Birmingham | Alabama | 35294 | — |
| Georgetown University: Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| University of Florida: Shands Cancer Center | Gainesville | Florida | 32610 | — |
| Memorial Cancer Institute | Hollywood | Florida | 33021 | — |
| University of Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Memorial Breast Cancer Center: Memorial West | Pembroke Pines | Florida | 33028 | — |
| Emory University: Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| Community Hospital of Anderson and Madison County, Inc | Anderson | Indiana | 46011 | — |
| Fort Wayne Oncology & Hematology, Inc. | Fort Wayne | Indiana | 46845 | — |
| IU Health Goshen Hospital | Goshen | Indiana | 46527 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Community Regional Cancer Center | Indianapolis | Indiana | 46256 | — |
| St. Vincent Hospital | Indianapolis | Indiana | 46260 | — |
| IU Health Arnett Cancer Center | Lafayette | Indiana | 47904 | — |
| Community Healthcare System: Monroe Medical Associates | Munster | Indiana | 46321 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46628 | — |
| Meritus Center for Clinical Research | Hagerstown | Maryland | 21742 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Washington University: Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68114 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45267 | — |
| Mercy Clinic Oncology & Hematology: McAuley | Oklahoma City | Oklahoma | 73120 | — |
| Pinnacle Health Cancer Center | Harrisburg | Pennsylvania | 17109 | — |
| Erlanger Health System | Chattanooga | Tennessee | 37403 | — |
| Joe Arrington Cancer Research and Treatment Center | Lubbock | Texas | 79410 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Froedtert/Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
| Aurora Health Care | Wauwatosa | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Breast Cancer trials
Other public records listing Breast Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07793721: Effects of Risk Presentation Format and Frequently Asked Questions on Breast Cancer Risk Skepticism Not yet recruiting
- NCT07789912: BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies Not yet recruiting
- NCT07781852: Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer Not yet recruiting
- NCT07781800: Navigation Interventions for Patients With Breast Cancer and High-risk Social Determinants of Health Not yet recruiting
- NCT07067138: A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) Recruiting
- NCT07776964: Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02101385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2023 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02101385 live on ClinicalTrials.gov.